Yasemin Denkboy Öngen1, Erdal Eren1, Özgecan Demirbaş1, Elif Sobu1, Sian Ellard2,3, Elisa De Franco2, Ömer Tarım1. 1. Bursa Uludağ University Faculty of Medicine, Department of Pediatric Endocrinology, Bursa, Turkey 2. University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, United Kingdom 3. Royal Devon and Exeter NHS Foundation Trust, Genomics Laboratory, Exeter, United Kingdom
Abstract
Objective: Neonatal diabetes mellitus (NDM) may be transient or permanent, and the majority is caused by genetic mutations. Early diagnosis is essential to select the patients who will respond to oral treatment. In this investigation, we aimed to present the phenotype and genotype of our patients with NDM and share our experience in a single tertiary center Methods: A total of 16 NDM patients from 12 unrelated families are included in the study. The clinical presentation, age at diagnosis, perinatal and family history, consanguinity, gender, hemoglobin A1c, C-peptide, insulin, insulin autoantibodies, genetic mutations, and response to treatment are retrospectively evaluated. Results: The median age at diagnosis of diabetes was five months (4 days-18 months) although six patients with a confirmed genetic diagnosis were diagnosed >6 months. Three patients had KCNJ11 mutations, six had ABCC8 mutations, three had EIF2AK3 mutations, and one had a de novo INS mutation. All the permanent NDM patients with KCNJ11 and ABCC8 mutations were started on sulfonylurea treatment resulting in a significant increase in C-peptide level, better glycemic control, and discontinuation of insulin. Conclusion: Although NDM is defined as diabetes diagnosed during the first six months of life, and a diagnosis of type 1 diabetes is more common between the ages of 6 and 24 months, in rare cases NDM may present as late as 12 or even 24 months of age. Molecular diagnosis in NDM is important for planning treatment and predicting prognosis. Therefore, genetic testing is essential in these patients.
Objective: Neonatal diabetes mellitus (NDM) may be transient or permanent, and the majority is caused by genetic mutations. Early diagnosis is essential to select the patients who will respond to oral treatment. In this investigation, we aimed to present the phenotype and genotype of our patients with NDM and share our experience in a single tertiary center Methods: A total of 16 NDM patients from 12 unrelated families are included in the study. The clinical presentation, age at diagnosis, perinatal and family history, consanguinity, gender, hemoglobin A1c, C-peptide, insulin, insulin autoantibodies, genetic mutations, and response to treatment are retrospectively evaluated. Results: The median age at diagnosis of diabetes was five months (4 days-18 months) although six patients with a confirmed genetic diagnosis were diagnosed >6 months. Three patients had KCNJ11 mutations, six had ABCC8 mutations, three had EIF2AK3 mutations, and one had a de novo INS mutation. All the permanent NDM patients with KCNJ11 and ABCC8 mutations were started on sulfonylurea treatment resulting in a significant increase in C-peptide level, better glycemic control, and discontinuation of insulin. Conclusion: Although NDM is defined as diabetes diagnosed during the first six months of life, and a diagnosis of type 1 diabetes is more common between the ages of 6 and 24 months, in rare cases NDM may present as late as 12 or even 24 months of age. Molecular diagnosis in NDM is important for planning treatment and predicting prognosis. Therefore, genetic testing is essential in these patients.
Authors: Abdelhadi M Habeb; Mohamed S F Al-Magamsi; Ihsan M Eid; Mohamed I Ali; Andrew T Hattersley; Khalid Hussain; Sian Ellard Journal: Pediatr Diabetes Date: 2011-11-08 Impact factor: 4.866
Authors: D Iafusco; M A Stazi; R Cotichini; M Cotellessa; M E Martinucci; M Mazzella; V Cherubini; F Barbetti; M Martinetti; F Cerutti; F Prisco Journal: Diabetologia Date: 2002-05-03 Impact factor: 10.122
Authors: Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Sarah E Flanagan; Elisa De Franco; Hana Lango Allen; Michele Zerah; Majedah M Abdul-Rasoul; Julie A Edge; Helen Stewart; Elham Alamiri; Khalid Hussain; Sam Wallis; Liat de Vries; Oscar Rubio-Cabezas; Jayne A L Houghton; Emma L Edghill; Ann-Marie Patch; Sian Ellard; Andrew T Hattersley Journal: Cell Metab Date: 2014-01-07 Impact factor: 27.287
Authors: Huseyin Demirbilek; Ved Bhushan Arya; Mehmet Nuri Ozbek; Jayne A L Houghton; Riza Taner Baran; Melek Akar; Selahattin Tekes; Heybet Tuzun; Deborah J Mackay; Sarah E Flanagan; Andrew T Hattersley; Sian Ellard; Khalid Hussain Journal: Eur J Endocrinol Date: 2015-03-09 Impact factor: 6.664
Authors: Lisa R Letourneau; David Carmody; Kristen Wroblewski; Anna M Denson; May Sanyoura; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley Journal: Diabetes Care Date: 2017-08-04 Impact factor: 19.112